Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

Connecting Science to Patient Care in Treatment of Psoriatic Arthritis Patient Care

Connecting Science to Patient Care in Treatment of Psoriatic Arthritis Patient Care

Science is moving forward in understanding the key inflammatory pathways involved in psoriasis and psoriatic arthritis, which has led to the development of targeted, effective therapies for patients with these diseases. But with these advances, it’s becoming more and more important for clinicians to understand how to choose treatment options appropriately and how to discuss them with patients.

  • Dr. Mease, Director, Rheumatology Research, University of Washington School of Medicine

    Philip J. Mease, MD
    Director of Rheumatology Research,
    Swedish Medical Center
    Clinical Professor
    University of Washington School of Medicine
    Seattle, Washington

  • Allan Gibofsky, MD, JD, MACR, FACP, FCLM

    Allan Gibofsky, MD, JD, MACR, FACP, FCLM
    Professor of Medicine, Healthcare Policy and Research Weill Medical College of Cornell University Attending Rheumatologist Hospital for Special Surgery
    New York, New York

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Krista Jaworski and Marianna Shershneva MD, PhD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Phillip Mease: AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
  • Faculty: Alan Gibofsky, MD, JD, MACR, FACP, FCLM: AbbVie, Celgene, Pfizer, Lilly, Amgen, Novartis

As a result of participation in this educational activity, participants should increase their ability to:

  • Describe

    Describe a current model explaining PsA pathophysiology and mechanisms of action of targeted therapies for PsA


  • Apply evidence about effectiveness and safety of targeted therapies for PsA and guiding principles for management of patients with PsA

  • Engage

    Engage patients with PsA in shared decision making regarding goals of treatment, development of treatment plan, and treatment modification

Activity Information

Target Audience
The target audience for this activity was rheumatologists and NP/PA rheumatology providers. Other healthcare professionals who treat patients with PsA may have benefited from participation.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interstate Postgraduate Medical Association is approved by the California Board of Registered Nursing, Provider Number 6971, for 0.5 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course.

This activity is approved for 0.5 contact hour(s) of continuing education (which includes up to .50 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19073794.  This activity was planned in accordance with AANP CE Standards and Policies.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, Interstate Postgraduate Medical Association, or Lilly.

The content of this activity was independently peer reviewed by two reviewers and two patients with psoriasis and psoriatic arthritis. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

This activity is provided by Forefront Collaborative in collaboration with Interstate Postgraduate Medical Association.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.